COST-UTILITY ANALYSIS AND EFFICIENCY FRONTIER APPROACH OF TAFASITAMAB IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Fahham, L. [1 ]
Dias, L. [2 ]
Amaral, L. Murta [2 ]
Mazzuco, C. [3 ]
Araujo, G. [3 ]
机构：
[1] ORIGIN Hlth, Sao Paulo, Brazil
[2] ORIGIN Hlth, Rio De Janeiro, RJ, Brazil
[3] Knight Therapeut, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE442
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Authors' Reply to Liedgens and Henske: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective''
    Wielage, Ronald C.
    Bansal, Megha
    Andrews, J. Scott
    Klein, Robert W.
    Happich, Michael
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2013, 11 (05) : 555 - 557
  • [22] Authors’ Reply to Liedgens and Henske: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
    Ronald C. Wielage
    Megha Bansal
    J. Scott Andrews
    Robert W. Klein
    Michael Happich
    Applied Health Economics and Health Policy, 2013, 11 (5) : 555 - 557
  • [23] Cost-Utility of Reduction Mammaplasty Assessed for the Brazilian Public Health System
    Mundim Araujo, Carlos Delano
    Veiga, Daniela Francescato
    Hochman, Bernardo Sergio
    Felipe Abla, Luiz Eduardo
    Salles Oliveira, Ana Carolina
    Novo, Neil Ferreira
    Veiga-Filho, Joel
    Ferreira, Lydia Masako
    AESTHETIC SURGERY JOURNAL, 2014, 34 (08) : 1198 - 1204
  • [24] Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy: a cost-utility analysis from the perspective of Chinese healthcare system
    Chen, Maolin
    Yu, Ying
    Yu, Baozhong
    Cao, Yudan
    Lou, Yake
    Ma, Yudong
    FRONTIERS IN NEUROLOGY, 2025, 16
  • [25] Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Barros, Bruno M.
    Correia, Marcelo G.
    Tura, Bernardo R.
    Magliano, Carlos S.
    VALUE IN HEALTH REGIONAL ISSUES, 2025, 48
  • [26] Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic StrokeA Canadian Healthcare Perspective
    Shannon E. Sinclair
    Luciana Frighetto
    Peter S. Loewen
    Rubina Sunderji
    Philip Teal
    Susan C. Fagan
    Carlo A. Marra
    PharmacoEconomics, 2001, 19 : 927 - 936
  • [27] Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system
    Psaltikidis, Eliane Molina
    da Silva, Everton Nunes
    Moretti, Maria Luiza
    Trabasso, Plinio
    Bello Stucchi, Raquel Silveira
    Aoki, Francisco Hideo
    de Oliveira Cardoso, Luis Gustavo
    Hofling, Christian Cruz
    Bachur, Luis Felipe
    Ponchet, Danilo da Fontoura
    Ceccato Colombrini, Maria Rosa
    Tozzi, Cintia Soarez
    Ramos, Rosana Fins
    Queiroz Costa, Sandra Mara
    Resende, Mariangela Ribeiro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (03) : 341 - 352
  • [28] COST-EFFECTIVENESS ANALYSIS OF NETUPITANT/ PALONOSETRON FOR CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Araujo, G.
    Silva, H. M.
    Picoli, R. M.
    VALUE IN HEALTH, 2023, 26 (12) : S93 - S93
  • [29] Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke - A Canadian healthcare perspective
    Sinclair, SE
    Frighetto, L
    Loewen, PS
    Sunderji, R
    Teal, P
    Fagan, SC
    Marra, CA
    PHARMACOECONOMICS, 2001, 19 (09) : 927 - 936
  • [30] Effectiveness and Cost-Utility of Interventions for Enuresis Treatment in Children and Adolescents From the Brazilian Single Health System Perspective
    Moretti, Eduarda
    Marcolino, Miriam Allein Zago
    Lima, Anna Myrna Jaguaribe de
    Lemos, Andrea
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 1 - 8
12345